Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Apr;96(16):e6606.
doi: 10.1097/MD.0000000000006606.

Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection

Chao He  1 , Wei Peng, Chuan Li, Tian-Fu Wen
Affiliations
Observational Study

Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection

Chao He et al. Medicine (Baltimore). 2017 Apr.

Abstract

There is limited information available concerning the effect of thymalfasin (Tα1) as an adjuvant therapy in hepatocellular carcinoma (HCC) patient who received liver resection. The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study. Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162). Clinical data, overall survival (OS), and recurrence-free survival (RFS) were compared. Prognostic factors were identified using multivariate analysis.After a median follow-up of 47.0 months, 134 patients (65%) had recurrence, and 62 patients (30.09%) died. The 1, 3, and 5-year OS rate of patients in group A was 97.7%, 90.6%, and 82.9%, respectively, and 95.1%, 80.5%, and 62.9%, respectively, for patients in group B (P = .014). The 1, 3, and 5-year RFS rate of patients in group A was 70.5%, 56.8%, and 53.3%, respectively, and 65.8%, 41.3%, and 32.1%, respectively, for patients in group B (P = .015). Multivariate analysis indicated that Tα1 was an independent prognostic factor for both OS (P = .015, hazard ratio 0.349, 95% confidence interval 0.149-0.816) and RFS (P = .019, hazard ratio 0.564, 95% confidence interval 0.349-0.910).Tα1 as an adjuvant therapy after liver resection may improve the prognosis of small HCC patients after liver resection.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart of the process for patients’ selection.
Figure 2
Figure 2
The graph shows the OS curve of group A (liver resection plus Tα1, n = 44) and group B (liver resection, n = 162). Group A had better OS than group B (log-rank test, P = .014). OS = overall survival, Tα1 = thymalfasin.
Figure 3
Figure 3
The graph shows the RFS curve of group A (liver resection plus Tα1, n = 44) and group B (liver resection, n = 162). Group A had better RFS than group B (log-rank test, P = .015). RFS = recurrence-free survival, Tα1 = thymalfasin.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. - PubMed
    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917. - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55. - PubMed
    1. Jeng WJ, Lin CC, Chen WT, et al. Adjuvant therapy for hepatocellular carcinoma after curative treatment. Dig Dis 2014;32:747–54. - PubMed
    1. Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Nat Acad Sci USA 1972;69:1800–3. - PMC - PubMed

Publication types

MeSH terms